Purpose: We aimed to determine whether intravitreal dexamethasone as an adjuvant to intravitreal antibiotics is beneficial in the treatment of suspected bacterial endophthalmitis after cataract surgery. Methods: Randomized, placebo-controlled superiority trial in three tertiary referral centres in the Netherlands. Patients with suspected bacterial endophthalmitis within 6 weeks after cataract surgery were eligible. A diagnostic vitreous biopsy was taken for culture, and patients received intravitreal injections of 400 lg dexamethasone (without preservatives) or placebo, in addition to 0.2 mg vancomycin and 0.05 mg gentamicin. The vancomycin and dexamethasone or placebo injections were repeated once at day 3 or 4. Primary outcome measure was best-corrected visual acuity (BCVA) at 1 year. Results: Between 1 November 2004 and 1 March 2014 (excluding two interruptions totalling 20 months), 324 eligible patients presented. A total of 167 patients (81 dexamethasone, 86 placebo) were available for the intention-to-treat analysis. Biopsies of 114 patients (68%) were culture-positive. Final BCVA did not differ between the dexamethasone and the placebo group (logMAR 0.31 AE 0.58 versus 0.27 AE 0.50; p = 0.90), nor did the number of patients with final vision of no light perception (LP, 7 versus 13). Pain, corneal oedema, the absence of a red fundus reflex on presentation, LP on presentation and culture of virulent pathogens from biopsy were statistically significantly associated with an unfavourable visual outcome. Conclusion: Intravitreal dexamethasone without preservatives as an adjuvant to intravitreal antibiotics does not improve visual acuity (VA) in patients treated for suspected bacterial endophthalmitis after cataract surgery.
Introduction
Bacterial endophthalmitis is a rare but severe complication of intraocular surgery which may rapidly lead to permanent visual loss. In the damage inflicted on the ocular structures in endophthalmitis, bacteria, which replicate and release toxins and immunoreactive components, act in concert with the host inflammatory response (Callegan et al. 2002; Gower et al. 2015) . More recent studies, employing optical coherence tomography and histological examination of eyes with postoperative endophthalmitis, offer further insight into the pathological processes involved (Solborg Bjerrum et al. 2016) . Although the risk of endophthalmitis is not particularly high after cataract surgery, the sheer volume of cataract operations being carried out means that postoperative endophthalmitis after cataract surgery is encountered relatively frequently. Several important issues concerning treatment and management of endophthalmitis after cataract surgery have been addressed in the landmark endophthalmitis vitrectomy study (EVS) (Endophthalmitis Vitrectomy Study Group 1995) . This study demonstrated that systemic antibiotics have no beneficial effect on final VA; additionally, an initial vitreous biopsy was equally beneficial to core vitrectomy. However, in a post hoc analysis, in the subgroup of patients with presenting vision of LP, core vitrectomy had superior visual outcome to vitreous biopsy.
One issue not studied in the EVS, however, was the possible adjuvant use of intravitreal dexamethasone, as all patients received a 5-day course of high-dose oral prednisone. In the treatment of bacterial meningitis, the adjuvant use of intravenous corticosteroids, in addition to intravenous antibiotics, was shown to reduce disease morbidity and mortality, at least in cases of pneumococcal infection (De Gans & van de Beek 2002) . Corticosteroids are considered to limit recruitment of leucocytes, stabilize the blood-brain barrier (which is quite similar in nature to the blood-retinal barrier), modify the expression of inflammatory cytokines and stimulate production of cytoprotectants. However, systemic exposure to high-dose prednisone, even for a short period only, particularly in the elderly cataract patient, has been associated with gastric haemorrhage and decompensation of underlying medical conditions such as diabetes mellitus.
Numerous animal studies have shown a beneficial effect of adding intraocular steroids on the outcome of endophthalmitis (Maxwell et al. 1991; Jett et al. 1995; De Kaspar et al. 2008; Liu et al. 2008) , two showed no effect (Ermis et al. 2007; Sakalar et al. 2011) and only one study showed a negative effect (Meredith et al. 1996) .
In patients with endophthalmitis, no conclusive results on intravitreally administered corticosteroids (in all instances dexamethasone 400 lg) have so far been reported. One randomized trial, in 61 postoperative and posttraumatic endophthalmitis patients, showed that intravitreal dexamethasone reduced early inflammation (Das et al. 1999) , whereas a retrospective comparative study of 57 patients with postcataract endophthalmitis suggested a worse visual outcome when intravitreal steroids were administered (Shah et al. 2000) . A small, singlecentre randomized placebo-controlled trial in 29 patients showed better visual outcome in patients with suspected bacterial endophthalmitis when treatment with intravitreal antibiotics was combined with intravitreal dexamethasone (Gan et al. 2005a) . A more recent prospective, randomized placebo-controlled clinical trial of 62 patients, with presumed bacterial endophthalmitis after cataract surgery, glaucoma surgery or trauma, suggested a trend towards a better outcome in the intravitreal steroid subgroup (32 patients; p = 0.33) (Albrecht et al. 2011) . A recent systematic review of three above-mentioned randomized controlled trials (RCT) of 95 patients with presumed bacterial endophthalmitis after cataract surgery found that adjunctive intravitreal steroid to intravitreal antibiotic is of uncertain benefit (Kim et al. 2017) .
To address this issue with a sufficiently powered study, we initiated a multicentre placebo-controlled clinical trial of endophthalmitis in postcataract surgery patients using intravitreal dexamethasone without preservatives in combination with a modified EVS treatment regimen, aimed at optimizing efficacy of antibiotic treatment while reducing potential drug side-effects.
Patients and Methods
Starting from November 2004, consecutive patients with a diagnosis of suspected bacterial postcataract surgery endophthalmitis presenting at the University Medical Centre Utrecht, Radboud University Nijmegen Medical Centre or the Rotterdam Eye Hospital were asked to participate in this study. Written informed consent was asked from all participants. The study protocol was approved by the Medical Ethics Committee of the Erasmus University Rotterdam and is registered in the Netherlands Trial Register (NTR 189). Patients were randomized to receive either intravitreal dexamethasone or placebo, adjunctive to intravitreal antibiotic treatment. In batches randomized per 10 patients, the trial pharmacist prepared two vials for each patient in a plastic bag (each patient had either two dexamethasone vials or two placebo vials, in similar vials containing indistinguishable clear fluids) and stored in the refrigerator in the operation centres.
Suspected postoperative bacterial endophthalmitis was defined as follows: (i) a decrease in VA and (ii) an inflammatory response deemed excessive (relative to the anticipated course after surgery) with cells or hypopyon in the anterior chamber or posterior segment with reduction or loss of fundus detail. Patients were excluded when (i) the cataract surgery had been performed more than 6 weeks previously; (ii) the expected postoperative VA was 20/100 (logMAR 0.7) or worse, due to the presence of any visually consequential comorbidity; (iii) systemic or subconjunctival antibiotics had been administered; and (iv) there was suspicion of fungal infection.
Patients underwent a full ophthalmological examination. The following findings were noted on a case record form: date of cataract surgery, pain, presenting VA, intraocular pressure, presence of corneal oedema, presence of hypopyon and presence of a red fundus reflex.
Our treatment approach has been described previously (Gan et al. 2001 (Gan et al. , 2005b Lindstedt et al. 2014) . In short, a vitreous diagnostic biopsy with a 23-gauge vitreous cutter was taken in all patients, including those with VA of LP only. Undiluted vitreous was collected for Gram-staining and culture before the start of empiric antibiotic therapy; the vitreous was plated within 2 hr and cultured aerobically and anaerobically. Immediately after the vitreous biopsy was taken, patients received an intravitreal injection of 0.2 mg vancomycin in 0.1 ml phosphate-buffered saline and 0.05 mg gentamicin in 0.1 ml phosphate-buffered saline, followed by 400 lg dexamethasone sodium diphosphate or placebo in 0.1 ml in sodium hydroxide-buffered saline, each without preservatives and with only 0.5 mg/ml sodium edetate, specifically manufactured by Delft Pharmacy, Erasmus University and Haarlemse Hospital Pharmacy under Good Manufacturing Practice. The intravitreal injection of 0.2 mg vancomycin and dexamethasone or placebo was repeated once within 3-4 days.
When Gram-staining or culture of the vitreous biopsy revealed Gramnegative bacteria, 1 mg ceftazidime was injected intravitreally, followed by intravenous ceftazidime (6 g per day) for 10 days (Berkhout et al. 2003) .
After biopsy, patients used prednisolone acetate 1% eye drops six times per day in a tapering schedule over the next 6 weeks and atropine 1% two times per day for 3 weeks. Additional procedures were allowed for the following indications, if the treating surgeon thought it to be in the patients' best interest: increasing inflammation [an increase in hypopyon, fibrin or intraocular lens (IOL) encapsulation], an increase in corneal thickness, increased pain, nonclearing opacities of the media, macular pucker and retinal detachment.
Complete ophthalmic examination was repeated 4 and 10 weeks, 6 months and 12 months after inclusion. When patients declined to visit the study hospitals, we attempted to retrieve the data of their 12-month visit to their referring ophthalmologist.
Snellen notation vision was converted to logMAR. Primary outcome of this study was BCVA at 12 months. In patients with follow-up between 6 and 12 months, as well as with patients with follow-up shorter than 12 months due to evisceration, we applied a last observation carried forward policy. In patients, whose last measured BCVA was later than 12 months, the last observation was carried backwards.
A sample size of 63 patients in each arm for our RCT was calculated, to allow the detection of an effect of 0.2 logMAR with an estimated standard deviation (SD) = 0.4 (Gan et al. 2005a) , power P = 0.80 and a significance level of alpha = 0.05 (2-sided). To account for patients with a (functionally) lost eye or for loss of followup, we aimed to recruit approximately 30% more patients (n = 82). An intention-to-treat analysis was performed to analyse the effect of dexamethasone or placebo on VA at 1 year. To allow the inclusion of functional outcomes of all patients in the analysis, dummy log-MAR values were introduced for LP present (LP+; 3.5) and LP absent (LPÀ; 4.0). For allocation and other dichotomous variables, a Mann-Whitney U-test was performed; variables with more than two categories were analysed with the Kruskal-Wallis Htest. December 2008, totalling 20 months, the study drug was not available, and enrolment of patients was temporarily interrupted. Because of these two interruptions, a belated start in one centre, and enrolment during only the first period in another centre, it took longer than anticipated to recruit the required number of patients. During active enrolment periods, a total of 324 patients with suspected endophthalmitis after cataract surgery presented to the three participating departments. Reasons for excluding patients were as follows: inclusion criteria not met -24 patients; refused to participate -46 patients; failure to ask to participate -85 patients. In total, 169 patients were enrolled in the study between November 2004 and March 2014. Two patients, erroneously included with endophthalmitis following secondary implant, were subsequently removed.
Results

Enrolment of patients
We have not been able to retrieve the written informed consent form of 35 patients. Because informed consent had been obtained at the time of inclusion and we had planned to perform an intentionto-treat analysis, we have included these patients in our analysis.
Nineteen patients did not attend their 52-week follow-up (reasons: two deceased, 17 unable or unwilling to show up for follow up), and last observation carried forward was applied.
In 20 patients with final vision of LP or no LP (including 10 patients who underwent evisceration), we also applied last observation carried forward. The last follow-up of the two patients, who passed away during the study, was 47 and 144 days, respectively. The mean AE SD follow-up of the 17 patients, who underwent evisceration, was 115 AE 52 days in the treatment group and 82 AE 46 days in the placebo group.
Nine patients did not receive a correct second injection. Two patients had their first dexamethasone injection followed by placebo: both were analysed in the dexamethasone group. Seven patients did not receive a second injection: two in the placebo group and five in the dexamethasone group: all these patients were analysed as they were allocated.
Thus, 167 patients qualified for an intention-to-treat analysis, with 81 patients allocated to dexamethasone and 86 to placebo (Fig. 1) .
Preoperative data
The baseline characteristics of the study patients are given in Table 1 . There was no difference between the dexamethasone and the placebo group.
Microbiological findings
A vitreous biopsy was obtained from 165 patients; due to inability to perform a vitreous tap successfully, only an anterior chamber tap was performed in two patients. One hundred and fourteen specimens (68%) showed growth of micro-organisms. Of 114 positive bacterial cultures, 70 were Gram-positive coagulase-negative staphylococci, 34 were other Grampositive micro-organisms, and 10 were Gram-negative micro-organisms (Table 2 ). There was no difference in the types of cultured micro-organisms or the rate of negative cultures between the dexamethasone and placebo group (Table 3) .
Reoperations
The number and indication for reoperations were similar in both groups (Table 3) .
Visual outcome
The number of eviscerations and number of patients who lost LP were comparable in both groups (Table 3) . Ten patients (three in the dexamethasone group, seven in the placebo group) underwent evisceration of the infected eye; 10 patients lost LP (four in the dexamethasone and six in the placebo group).
Final VA was similar in both groups (Table 3) .
Factors associated with poor visual outcome
Thirty-nine patients presented with LP, of whom seven were eviscerated and eight had a final vision of less than logMAR 1.6 (20/800). Factors associated with poor visual outcome are given in Table 4 . Visual outcome by cultured microbiological agent is given in Table 5 . Sixteen of 20 patients who lost LP or underwent evisceration had been infected by Gram-positive micro-organisms other than coagulase-negative staphylococci or by Gram-negative micro-organ isms.
Data of patients not included in the study
Data on excluded patients (n = 98) were available from two of three participating study sites. The culture profile and proportion of patients presenting with LP vision were similar between the study group and the excluded patients (Table 6) .
Discussion
This is the first multicentre RCT assessing the value of adding intravitreal dexamethasone without preservatives, to antibiotic treatment in patients with endophthalmitis after cataract surgery. No benefit of adjuvant steroid use in these patients was demonstrated, which suggests that this intervention may be omitted.
This conclusion confirms the recent report of Koehrer et al. (2015) that early or late addition of adjuvant steroids makes no difference in patients with suspected endophthalmitis after cataract surgery, as well as the findings of a recent systematic review (Kim et al. 2017) . As the currently available off-label formulations of dexamethasone contain a toxic or near toxic content of parabens, our finding may not only obviate the use of an ineffective measure, but even improve treatment by ending the use of a potentially toxic agent.
Strong points of this study were the double-blind design, the high percentage of positive vitreous cultures, the sustained sensitivity of the pathogens to the antibiotics chosen and the use of dexamethasone without preservatives. Weak points include the long recruitment period, due to the relative low rate of inclusion in the study, recruitment interruptions due to unavailability of the study drug and a proportion of patients not completing 1-year follow-up. Also, in most patients, final VA was recorded under clinical followup settings rather than with study protocol ETDRS charts.
For these shortcomings, there are, however, 'real-life clinical research' reasons. The generally late-in-the-day presentation and the short time available due to the urgency of working patients up for surgery combine to distract the involved physician from recruiting the patient for a randomized study. A large proportion of the study participants were referred to the participating sites following cataract surgery elsewhere. A plausible reason for loss of follow-up is the unwillingness of the patients to travel to the study site once the acute part of their treatment was over or the unwillingness to return to the referring clinic where the original complication occurred.
Nevertheless, patients in our study represent a fair sample of all patients presenting with suspected postcataract bacterial endophthalmitis, at least in the two centres where recruitment was relatively high: 159 patients in the study of 324 patients presenting. The major risk characteristics of the study patients (LP only at presentation and pathogen virulence) were not statistically different from the excluded patients.
We used preservative-free, specifically prepared dexamethasone for this study, because preservative-related toxicity was shown to be the limiting factor in intravitreal dexamethasone administration (Kwak & D'Amico 1992) . Earlier, we had to abort a prior RCT (Gan et al. 2005a) , because the formulation Decadron used then (dexamethasone sodium diphosphate, 20 mg/ml, with 1 mg/ml paraben as preservative, resulting in the acceptable content of 0.025 mg paraben/ml) was taken off the market in 2002. Unfortunately, the production of our study drug was interrupted twice during the study, because successive manufacturers had to suspend production due to the Health Authority's progressively stricter regulations.
As did other investigators before (Endophthalmitis Vitrectomy Study Group 1995; Koehrer et al. 2015) , we anticipated a beneficial effect of the adjuvant use of dexamethasone, although the opposite effect has also been suggested. Dexamethasone is used to decrease the bystander effect of immunological inflammation elicited by the infecting pathogen. A combined use of dexamethasone and antibiotics is supported by its use in patients with bacterial meningitis (an infection sharing many features with endophthalmitis), although this has been challenged ( Van de Beek et al. 2010 ). Likewise, a beneficial effect of corticosteroids on the outcome of endophthalmitis is observed in most animal models of endophthalmitis (Maxwell et al. 1991; Jett et al. 1995; De Kaspar et al. 2008; Liu et al. 2008) and suggested in two of four controlled but underpowered studies in patients (Das et al. 1999; Shah et al. 2000; Gan et al. 2005a; Albrecht et al. 2011) .
However, dampening the immune reaction during ongoing infection may be hazardous, as antibiotics should always be viewed as auxiliary to the immune response against the invading organisms. Moreover, it may initially obscure the severity of infection in case of an inappropriate choice of medication, as in fungal infections. In a study in rabbits, Meredith et al. (1996) report a worse outcome when intravitreal steroids are used in combination with antibiotics, and in two other studies (Ermis et al. 2007; Sakalar et al. 2011) , no benefit was noted. In a study in rabbits, the use of dexamethasone was suggested to lead to decreased vancomycin concentrations (Smith et al. 1991) . Such an effect, however, could not be confirmed in patients (Gan et al. 2005b ) nor did we find an increased safety risk during (Lindstedt et al. 2014) or at the conclusion of our study.
Of note, the treatment regimen we applied differs from the approach taken in the EVS (Endophthalmitis Vitrectomy Study Group 1995) in two aspects. First, we injected intravitreal vancomycin twice (instead of once). Thus, a much lower dose than that in the EVS could be applied to minimize risk of antibiotic dose-related toxicity (Gan et al. 2001) . Our concern regarding the safety of the commonly recommended 1 mg vancomycin dose was confirmed by a recent report of isolated vancomycin retinotoxity (Witkin et al. 2015) . For the initial empiric coverage of Gramnegative bacteria, we chose to use the aminoglycoside gentamicin in a dose half the concentration of the lowest concentration reported to be toxic in patients (Campochiaro & Conway 1991; Campochiaro & Lim 1994) . In a more recent and focused study in rabbits and rats (Hancock et al. 2005) , reversible electroretinography changes occurred during a 1 mg/ml gentamycin perfusion, a concentration an estimated 16 times higher than the peak concentration after injection of 0.05 mg gentamycin in a patient. Nevertheless, due to the uncertain diffusion behaviour of intravitreally injected gentamycin into an eye that is temporarily hypotonous after vitreous biopsy, the actual concentration at the level of the macula and the disc remains hard to predict. In cases of confirmed Gramnegative infection, treatment was continued with a low loading dose of ceftazidime injected intravitreally and maintained by intravenous infusion (Berkhout et al. 2003) . Gentamicin is preferred over ceftazidime in the empiric setting because of its synergetic effect with vancomycin on the most frequently encountered Gram-positive bacteria (Gan et al. 2001 (Gan et al. , 2005b Cottagnoud et al. 2002) . Recent reports on microbial sensitivity to antibiotics in endophthalmitis after cataract surgery support the choices in antibiotics made in 2003 (Gentile et al. 2014; Holland et al. 2014; Gower et al. 2015) . Second, in all patients, including those presenting with LP only, we simply performed vitreous biopsy and not core vitrectomy, because we chose not to exclude patients where iris detail was not visible or whose cornea was not sufficiently clear to allow vitrectomy (as in the EVS). The presenting VA of patients, the number of culture-positive patients, the type of pathogens and the proportion of patients with diabetes mellitus are comparable between our study and the EVS. In terms of outcome, a vision of logMAR 0.7 (20/100) or better was achieved in 79% of patients as compared to 74% in the EVS. A vision of logMAR 0.3 (20/40) or better was recorded in 69% of patients in our study compared to 53% of patients in the EVS.
The outcome of the 39 patients presenting with LP appears worse [18% evisceration and 21% less than logMAR 1.6 (20/800)] than in the best treatment outcome subgroup of the EVS (those with core vitrectomy, n = 55: 7.3% enucleated and 13% <20/800). Although this difference was not statistically significant (Kolmogorov-Smirnov: p = 0.42), these data encourage further study of the effectiveness of vitrectomy in unselected patients with LP only. Another difference between the EVS and our study is that half of our patients received adjuvant steroids, with two consecutive intravitreal peak concentrations of around 100 lg/ml dexamethasone, whereas all EVS patients received 60 mg oral prednisone (equivalent to 8 mg dexamethasone) for 5-10 days, which results in an estimated intravitreal peak concentration of 6 ng/ml dexamethasone (Weijtens et al. 1998) . Dexamethasone overdosing by the repeated injections is not a concern, as the estimated half-life of intravitreal dexamethasone is 5.5 hr (Gan et al. 2005b ). It may be argued that the intravitreal injections of steroids led to too high concentrations and that much lower dosing (as in the EVS) might be more beneficial. Given the excellent visual outcomes in both arms of our study, this is unlikely.
In conclusion, our study establishes that the use of intravitreal dexamethasone without preservatives, as an adjuvant to intravitreal antibiotics, has no beneficial effect and should be abandoned. As the currently available offlabel formulations of dexamethasone contain a toxic or near toxic content of parabens, our finding may not only obviate the use of an ineffective measure but even improve treatment by ending the use of a potentially toxic agent. 
